FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of	1934
or Section 30(h) of the Investment Company Act of 1940	

1. Name and Address of Reporting Person [*] HANCOCK DANIEL M			2. Issuer Name and Ticker or Trading Symbol <u>Cryoport, Inc.</u> [CYRX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
					Director	10% Owner	
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		Officer (give title below)	Other (specify below)	
C/O CRYOPORT	INC.		10/20/2021				
112 WESTWOOI	D PLACE, SUITE 35	50					
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	idual or Joint/Group Filing (Che		
BRENTWOOD	TN	37027			Form filed by One Reporting Form filed by More than On	5	
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	10/20/2021		M ⁽¹⁾		3,783	A	\$14.35	8,410	D	
Common Stock	10/20/2021		S ⁽¹⁾		3,783	D	\$ 75.1745 ⁽²⁾	4,627	D	
Common Stock	10/21/2021		M ⁽¹⁾		11,217	A	\$14.35	15,844	D	
Common Stock	10/21/2021		S ⁽¹⁾		5,900	D	\$ 75.289 ⁽³⁾	9,944	D	
Common Stock	10/21/2021		S ⁽¹⁾		5,317	D	\$ 76.2443 ⁽⁴⁾	4,627	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

5. Number of Derivative Securities 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 1. Title of 3. Transaction 3A. Deemed 8. Price of Derivative 9. Number of 10 11. Nature of Indirect Execution Date, Derivative Conversion Transaction derivative Ownership (Month/Day/Year) Security (Instr. 3) or Exercise Price of Derivative if any (Month/Day/Year) Code (Instr. Security (Instr. 5) Securiti Form: Beneficial Acquired (A) or Disposed of (D) (Instr. 3, 4 Direct (D) 8) 3 and 4) Beneficially Ownership or Indirect (I) (Instr. 4) Derivativ Security Owned (Instr. 4) Following and 5) Reported Transaction(s) Amount (Instr. 4) Number of Shares Date Expiration Date Code v (A) (D) Exercisable Title Option to **M**⁽¹⁾ \$14.35 10/20/2021 05/02/2029 3,783 purchase common 3,783 (5) \$<mark>0</mark> 11,217 D Stock . stock

Explanation of Responses:

\$14.35

Option to

purchase common stock

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021.

M⁽¹⁾

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$74.90 to \$75.40, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(5)

05/02/2029

11,217

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$74.90 to \$75.89, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$75.91 to \$76.63, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the twelve (12) months beginning on 05/02/2019.

/s/ Daniel Hancock

** Signature of Reporting Person

Common Stock

11,217

\$<mark>0</mark>

<u>10/22/2021</u> Date

0

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

10/21/2021

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.